This note responds to the Department of Health's review, led by Professor Mike Richards, into the consequences of additional private drugs for NHS care.
Since its beginnings, the NHS has had a close relationship with the pharmaceutical industry. While not an official public-private partnership (PPP) there has been, in effect, an implicit PPP for pharmaceutical research and provision. This partnership has been an undoubted economic success. However, the interests of users of the health ...
How are top-ups distinct from other charges in the NHS and why have they become such a contentious issue now? This briefing gives some background on the relevant legislation and guidance in this area. [Introduction]
The National Institute for Health and Clinical Excellence (NICE) is acknowledged as a world leader in its field, yet the prevailing media image of NICE is as a controversial mechanism for denying patients expensive new drugs. Teresa Poole looks at how NICE appraises new and existing drugs through clinical and ...
Since its beginnings, the NHS has had a close relationship with the pharmaceutical industry. While not an official public-private partnership (PPP) there has been, in effect, an implicit PPP for pharmaceutical research and provision. This partnership has been an undoubted economic success. However, the interests of users of the health ...
As part of their work for North Thames Research and Development, the King's Fund collected data on all Betaferon users from December 1995 to September 1996 in the North Thames region. They also organised discussion groups with 24 potential or actual users of the drug. The report looks at who ...
This project followed the introduction of beta-interferon in one health region. It provided the opportunity to pilot many helpful approaches to the active management of drugs in health authorities. The report concludes that many of the approaches used in this situation were successful and could be applied to future similar ...
This report addresses two questions: which factors influence people with relapsing remitting MS to come forward for new drug therapies?, and what do these group of people with MS want from an organisation such as the Multiple Sclerosis Society (MSS)? In addressing the first question, the authors discuss various discouraging ...